Related Experiment Video
Updated: Apr 28, 2026
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development
Binh Vu1, Peter Wovkulich1, Giacomo Pizzolato1
1Discovery Chemistry, Discovery Oncology, Discovery Technologies, Non-Clinical Development, Roche Research Center, Hoffmann-La Roche, Inc. , 340 Kingsland Street, Nutley, New Jersey 07110, United States.
Abstract:
The p53 tumor suppressor is a potent transcription factor that plays a key role in the regulation of cellular responses to stress. It is controlled by its negative regulator MDM2, which binds directly to p53 and inhibits its transcriptional activity. MDM2 also targets p53 for degradation by the proteasome. Many tumors produce high levels of MDM2, thereby impairing p53 function. Restoration of p53 activity by inhibiting the p53-MDM2 interaction may represent a novel approach to cancer treatment. RG7112 (2g) is the first clinical small-molecule MDM2 inhibitor designed to occupy the p53-binding pocket of MDM2. In cancer cells expressing wild-type p53, RG7112 stabilizes p53 and activates the p53 pathway, leading to cell cycle arrest, apoptosis, and inhibition or regression of human tumor xenografts.
Insights
Inhibiting MDM2 with RG7112 reactivates the p53 tumor suppressor pathway. This approach shows promise for cancer treatment by stabilizing p53 and inducing tumor regression.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- The p53 tumor suppressor is crucial for cellular stress response but is often inhibited by MDM2 in cancers.
- MDM2 negatively regulates p53 by blocking its transcriptional activity and targeting it for proteasomal degradation.
- Elevated MDM2 levels in tumors compromise p53 function, representing a therapeutic vulnerability.
Purpose of the Study:
- To evaluate RG7112, a novel small-molecule inhibitor targeting the p53-MDM2 interaction.
- To investigate the potential of restoring p53 activity as a cancer treatment strategy.
Main Methods:
- RG7112 was designed to bind to the p53-binding pocket of MDM2.
- The effects of RG7112 on p53 stabilization and pathway activation were assessed in cancer cells with wild-type p53.
- Tumor xenograft models were used to evaluate in vivo efficacy.
Main Results:
- RG7112 effectively stabilized p53 in cancer cells expressing wild-type p53.
- Activation of the p53 pathway by RG7112 led to cell cycle arrest and apoptosis.
- RG7112 demonstrated inhibition or regression of human tumor xenografts.
Conclusions:
- Inhibiting the p53-MDM2 interaction with RG7112 reactivates the p53 tumor suppressor pathway.
- RG7112 represents a promising therapeutic agent for cancers characterized by wild-type p53 and MDM2 overexpression.
